Drug Profile
DPX RSV Vaccine
Alternative Names: DepoVax™; DPX-RSV (A); DPXRSV; Respiratory syncytial virus vaccineLatest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator Immunovaccine
- Developer IMV
- Class Respiratory syncytial virus vaccines; Viral vaccines
- Mechanism of Action Immunostimulants; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(In volunteers) in Canada (Parenteral)
- 05 Oct 2018 DPX-RSV is still in phase I for Respiratory syncytial virus (RSV) infections in Canada (IMV pipeline, October 2018)
- 28 Sep 2018 Immunogenicity data from bovine animal studies in Respiratory syncytial virus (RSV) infections released by IMV